The effect of drugs used in rheumatology for treating SARS-CoV2 infection

Autor: Gianfranco Miceli, Donatella Sangari, Elisabetta Gerratana, Fabiola Atzeni, Ignazio Francesco Masala, Laura La Corte, Valeria Nucera, Manuela Giallanza
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
2019-20 coronavirus outbreak
medicine.medical_specialty
China
Coronavirus disease 2019 (COVID-19)
viruses
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Treatment outcome
Clinical Biochemistry
medicine.disease_cause
Antiviral Agents
03 medical and health sciences
0302 clinical medicine
Rheumatology
Internal medicine
Drug Discovery
medicine
Humans
skin and connective tissue diseases
Coronavirus
Pharmacology
Clinical Trials as Topic
Sulfonamides
business.industry
SARS-CoV-2
Tumor Necrosis Factor-alpha
fungi
virus diseases
COVID-19
medicine.disease
respiratory tract diseases
COVID-19 Drug Treatment
Pneumonia
030104 developmental biology
Treatment Outcome
Purines
030220 oncology & carcinogenesis
Antirheumatic Agents
Azetidines
Cytokines
Pyrazoles
business
Immunosuppressive Agents
Zdroj: Expert Opinion on Biological Therapy
ISSN: 1744-7682
1471-2598
DOI: 10.1080/14712598.2020.1817372
Popis: SARS-CoV-2 is a novel coronavirus that was first isolated from a group of patients hospitalized with pneumonia in China at the end of 2019, and, in February 2020, the syndrome it caused was named coronavirus disease 2019 (COVID-19) by the World Health Organization. In the absence of specific antiviral treatments capable of neutralizing the etiological agent, one therapeutic approach is to control the cytokine storm responsible for the most severe forms of the disease. The characteristic cytokine profile of severely affected patients is increased levels of interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, and tumor necrosis factor alpha (TNF-α).This article discusses the pathogenesis of COVID-19 as a rationale for using the biological and targeted synthetic drugs used in rheumatology (anti-TNF, anti-IL-1 and anti-IL-6 agents and baricitinib) to treat the disease, and provides key information concerning their potential benefits and adverse effects.Interleukin inhibition seems to be a promising means of treating COVID-19 patients when respiratory function declines (or even earlier) if there are laboratory data indicating the presence of a cytokine storm because the interleukins are key drivers of inflammation. However, it is important to consider the risks and benefits of biological agents carefully, and critically analyze the evidence concerning their use in COVID-19 patients.
Databáze: OpenAIRE
Externí odkaz: